On November 22nd, the Company’s Board of Directors agreed to the delisting of all the shares representing the capital stock of AB-BIOTICS, SA from the Alternative Stock Market, as well as the delegation of powers in favour of the Executive Directors to the aforementioned effects, so that they may act on behalf of and in representation of the Company to execute actions and sign documents, public and/or private, and to request and complete the delisting process in compliance with the resolutions approved by the General Board and the Company’s Board of Directors. Therefore, as of today, November 25th, it’s not possible to contract any shares of AB-Biotics.
Additionally, Kaneka Europe Holding Company NV has requested that the Company to notify the market that, in the event that any of the remaining minority shareholders who still hold shares of the Company wish to sell their shares (at the same price as the delisting offer of 5 Euros per share), once the Company is finally delisted, they may contact the following:
EBN Banco de Negocios, S.A. (+34 917009844) Mr. Sergio García Sendón – Director of Capital Markets (Debt / Equity) (firstname.lastname@example.org)
Mr. Finbar Murray – Director of Treasury and Capital Markets (email@example.com)
Mr. Enrique Diez – Associate of Treasury and Capital Markets (firstname.lastname@example.org)